Continuing Systemic Treatment in Cutaneous T-cell Lymphoma Associated With Lower Healthcare Costs
March 20, 2019 – Mary Caffrey
March 20, 2019 – Laura Joszt
March 20, 2019 – Jaime Rosenberg
March 20, 2019 – Wallace Stephens
What We're Reading: Postpartum Depression Drug Approval; Marijuana and Psychosis; Mississippi Abortion Bill
March 20, 2019 – AJMC Staff
March 19, 2019 – Allison Inserro
March 19, 2019 – Samantha DiGrande
March 19, 2019 – Wallace Stephens
What We're Reading: Ohio Work Requirements; Healthcare Data Breaches; Patients Try to Lower Drug Costs
March 19, 2019 – AJMC Staff
March 18, 2019 – Samantha DiGrande
This Week in Managed Care: January 11, 2019
This week, the top managed care news included the FDA commissioner discussing boosting drug competition; BMS offering details on its acquisition of Celgene; and cancer mortality rates declining for the 25th consecutive year.
The FDA Commissioner looks to boost drug competition, Bristol-Myers Squibb's (BMS’) big purchase kicks off JP Morgan’s healthcare conference, and cancer survival increases, but the news isn’t all good.
Welcome to This Week in Managed Care, I’m Laura Joszt.
Gottlieb Discusses Promoting Drug Competition in 2019
FDA Commissioner Scott Gottlieb, MD, promised more steps to promote competition in 2019, as he addressed the JP Morgan Health Care conference in San Francisco. Gottlieb took questions remotely due to the government shutdown. He said the FDA will issue more guidance documents that will close the gap between product approvals and products that actually reach the market.
Said Gottleib: “If we bring more products to the market, that will promote price competition.”
Biosimilars and generic drugs can expect plenty of attention, and Gottlieb promised several items for these manufacturers:
- A long-awaited interchangeability guidance
- A policy on carving back indications
- An updated Purple Book, which is the list of licensed biological products
BMS and Celgene Discuss Merger
The JP Morgan meeting kicked off with a joint session for BMS and Celgene, where they announced their $74 billion merger. With stakes in similar fields and drugs that include Opdivo, Yervoy, and Eliquis, the marriage will drive more value in oncology, cardiology, and autoimmune diseases, according to BMS Chairman and chief executive officer (CEO) Giovanni Caforio. Pipeline products include five in Celgene’s portfolio, notably liso-cel, which would be the third CAR T-cell therapy.
Said Celgene CEO Mark J. Alles: “This is a scientific powerhouse; when you put together the innovation and the scientists who are at BMS with what we’ve built through our network of partners and our standalone company, the scientific prowess of this company is unparalleled.”
The JP Morgan meeting also brought news that Eli Lilly is buying LOXO Oncology for $8 billion. LOXO’s medicines target genetic mutations regardless of where they are in the body.
For more on the BMS acquisition, visit ajmc.com.
Cancer Mortality Rates Continue to Decline
For the 25th year in a row, the American Cancer Society reported a drop in the cancer mortality rate. That’s the good news. The bad news is that socioeconomic disparities are getting worse. The annual report, published in CA: A Journal for Clinicians draws on data from the National Center for Health Statistics and the National Cancer Institute. Thanks to decades of public health efforts to get people to quit smoking and earlier detection, much of the news is good:
- From its peak in 1991, the cancer death rate has dropped steadily about 1.5% a year.
- Death from lung cancer dropped 48% among men from 1990 to 2016, and 23% from 2002 to 2016 among women.
- Prostate cancer deaths dropped 51% from 1993 to 2016, and breast cancer deaths dropped 40% from 1989 to 2016.
The authors wrote: “These [poor] counties are low-hanging fruit for locally focused cancer control efforts, including increased access to basic healthcare and interventions for smoking cessation, healthy living, and cancer screening programs. A broader application of existing cancer control knowledge with an emphasis on disadvantaged groups would undoubtedly accelerate progress against cancer.”
Medical and Recreational Marijuana
This week, Annals of Internal Medicine, the leading journal for physicians in primary care for adults, published a series of perspectives on medical and recreational marijuana. Collectively, while the authors say the opioid crisis has created interest among physicians in finding alternatives to treat pain, regulatory and research gaps create challenges. Authors from the University of Pittsburg Medical Center Health Plan said marijuana’s status as a Schedule 1 drug prevents research and payer coverage.
Lead author Chester B. Good, MD, told The American Journal of Managed Care®: “It is my personal belief that insurers will need to consider nontraditional data, and eventually (assuming removal of legal constraints) can use these data for coverage decisions.”
CVS Discusses Aetna Acquisition
Finally, the JP Morgan conference offered both breaking news and updates on news from the past year. CVS Health CEO Larry Merlo told attendees that the integration with Aetna is offering new care coordination opportunities for patients. A concept store will open in Houston, Texas, and CVS will roll out programs to help patients manage chronic diseases, including:
- Cardiovascular disease
- Behavioral health
For all of us at the Managed Markets News Network, I’m Laura Joszt.
Thanks for joining us.